User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

3543

Interactions with Platform & by Email *

INTERACTIONS

638

Unique # Participated *

PARTICIPANTS

106

Responses Validated *

VALIDATIONS

31

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
  
   Rising Incidences of Glaucoma Demands Novel Medications.....II-1
Understanding of Treatment Patterns Imperative for Developing New Drugs.....II-1
How Widespread is the Disease?.....II-1
1$100
   Table 1: Worldwide Glaucoma Prevalence by Select Countries (includes corresponding Graph/Chart).....II-2
Aging Population & Environmental Factors Drive Growth.....II-2
Combination Drugs Become Mainstay Glaucoma Products.....II-2
1$350
   Is Marijuana A Potential Cure?.....II-3
Lack of Awareness Among Patients – A Prevailing Trend.....II-3
High Costs Discourage Patients from Receiving Treatment.....II-3
The All-Consuming Issue of Compliance.....II-3
1$100
   Competitive Landscape.....II-4
Table 2: Global Market for Glaucoma Pharmaceuticals (2008): Percentage Value Share Breakdown of Leading Players - Pfizer, Inc., Allergan, Inc., Merck & Co., Alcon, Ista Pharmaceuticals and Others (includes corresponding Graph/Chart).....II-4
1$350
   Current and Future Analysis.....II-51$100
   A Prelude.....II-6
Who’s At Risk?.....II-6
Leading Causes for Glaucoma.....II-6
Diagnosis.....II-6
1$100
   Symptom Free Progression: A Major Concern.....II-7
Types of Glaucoma.....II-7
Primary Glaucoma.....II-7
1$100
   Primary Open-Angle Glaucoma (POAG).....II-8
Acute Angle-Closure Glaucoma (AACG).....II-8
Developmental Glaucoma.....II-8
Secondary Glaucoma.....II-8
1$100
   Other Common Types of Glaucoma.....II-9
Pigmentary Glaucoma.....II-9
Pseudo-Exfoliation Glaucoma.....II-9
Neovascular Glaucoma.....II-9
Toxic Glaucoma.....II-9
1$100
   Glaucoma Treatment Strategies.....II-10
Drugs Used for Treating Glaucoma.....II-10
1$100
   A Quick Look at Major Drugs by Category.....II-11
Beta-Adrenergic Blockers or "Beta Blockers".....II-11
Profile of Major Drugs under the Category.....II-11
Timolol.....II-11
Levobunolol.....II-11
Carteolol.....II-11
1$100
   Metipranolol.....II-12
Betaxolol.....II-12
Side Effects of Beta-Blockers.....II-12
Alpha-Adrenergic Agonists.....II-12
Side Effects of Alpha-Adrenergic Agonists.....II-12
1$100
   Carbonic Anhydrase Inhibitors.....II-13
Profile of Major Drugs under the Category.....II-13
Acetazolamide.....II-13
Dorzolamide.....II-13
1$100
   Side Effects of Carbonic Anhydrase Inhibitors.....II-14
Prostaglandin Analogues.....II-14
Side Effects of Prostaglandin Analogues.....II-14
Miotics.....II-14
Side Effects of Miotics.....II-14
Epinephrine Compounds.....II-14
1$100
   Mydriatics & Cycloplegics.....II-15
Commercial Mydriatic-Cycloplegics.....II-15
Side Effects of Mydriatic-Cycloplegics.....II-15
Neuroprotective Drugs.....II-15
1$100
   Surgical Approach to Glaucoma Treatment.....II-16
Laser Surgery.....II-16
Laser Trabeculoplasty.....II-16
Argon Laser Trabeculoplasty (ALT).....II-16
Selective Laser Trabeculoplasty (SLT).....II-16
1$100
   Laser Peripheral Iridotomy (LPI).....II-17
Filtering Procedure.....II-17
Trabeculectomy.....II-17
Drainage Implant Surgery.....II-17
1$100
   Other Surgical Procedures.....II-18
Non-Penetrating Surgery.....II-18
Canaloplasty.....II-18
The Express Mini Glaucoma Shunt.....II-18
Trabectome.....II-18
1$100
   Novagali Obtains FDA Approval for Catioprost Phase III Trial.....II-19
X-Gen Obtains FDA Approval for Acetazolamide Injection.....II-19
Alcon Obtains EMEA Approval for Azarga® Ophthalmic Suspension.....II-19
1$100
   Santen Receives Clearance for Tapros™ in Japan.....II-20
Santen Obtains Marketing Clearance for Taflotan™ in Denmark.....II-20
Allergan Obtains FDA Clearance for Combigan.....II-20
1$100
   Alcon Receives Japanese Approval for Travatanz™ Solution.....II-211$100
   Alcon to Take Over Swiss Biotech Company, ESBATech.....II-22
Abbott Acquires Advanced Medical Optics.....II-22
Aton Pharma Purchases US Marketing Rights to Merck 's Timoptic.....II-22
1$100
   NicOx to Re-Acquire Rights to Glaucoma Drug from Pfizer.....II-23
Merck Inks Licensing Deal for Tafluprost with Santen.....II-23
1$100
   Sucampo Inks In-licensing Deal with R-Tech for Rescula.....II-24
Alcon Commences Construction of Pharmaceutical Manufacturing Facility.....II-24
Alcon Abandons Anecortave Acetate Development.....II-24
Pipex to Acquire Rights to Additional Usage of Oral Flupirtine.....II-24
1$100
   Othera Submits IND Application with FDA for OT-730.....II-25
Inspire Commences Phase I Trial of Glaucoma Candidate, INS117548.....II-25
Lexicon Begins Preclinical Development of LX7101 for Glaucoma.....II-25
Pipex Pharmaceuticals Changes Name to Adeona Pharmaceuticals.....II-25
1$100
   Warburg Pincus Acquires Bausch & Lomb.....II-26
Santen and R-Tech Extend Marketing Agreement for RESCULA® in Japan.....II-26
1$100
   Acadia Pharmaceuticals, Inc. (US).....II-27
Alcon Laboratories, Inc. (US).....II-27
1$100
   Allergan, Inc. (US).....II-28
Falcon Pharmaceuticals, Ltd. (US).....II-28
1$100
   Inotek Pharmaceuticals Corporation (US).....II-29
Inspire Pharmaceuticals, Inc. (US).....II-29
Lexicon Pharmaceuticals, Inc. (US).....II-29
1$100
   Merck & Co., Inc. (US).....II-30
NicOx S.A. (France).....II-30
Novartis International AG (Switzerland).....II-30
1$100
   Pfizer, Inc. (US).....II-31
Santen Pharmaceutical Co., Ltd. (Japan).....II-31
2$125
   Table 3: World Recent Past, Current & Future Analysis for Glaucoma Pharmaceuticals Market by Geographic Region – US and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-331$350
   Table 4: World 10-year Perspective for Glaucoma Pharmaceuticals Market by Geographic Region – Percentage Breakdown of Dollar Sales for US and Rest of World Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-341$350
   A. Market Analysis.....III-1
Glaucoma Market: A Quick Primer.....III-1
1$100
   Table 5: Glaucoma Pharmaceutical Products Prescription Volume in the US (2008 & 2009): Percentage Breakdown for Xalatan, Lumigan, Alphagan P, Travatan and Others (includes corresponding Graph/Chart).....III-2
Prevalence of Glaucoma – A Recapitulation of Facts.....III-2
Patent Expiries to Prune Glaucoma Market Size.....III-2
1$200
   Patent Expiries of Key Glaucoma Drugs in Recent Past, Current, and Future.....III-3
Leading Drugs to Lose Sheen.....III-3
1$100
   Table 6: Leading Glaucoma Pharmaceutical Products in the US (2008, 2010 & 2012): Percentage Breakdown of Value Sales for Xalatan/Xalcom, Cosopt, Lumigan, Travatan, Alphagan, Combigan, Generic Timolol and Others (includes corresponding Graph/Chart).....III-4
Research & Development.....III-4
Select Combination Therapeutics in Pipeline.....III-4
Ganfort (Lumigan/timolol) – Pending Approval.....III-4
1$200
   DuoTrav (Travatan/timolol) – Pending Approval.....III-5
Xalcom (Xalatan/timolol) – Pending Approval.....III-5
Azopt (brinzolamide/timolol) – Phase III.....III-5
Travatan/Azopt – Phase III.....III-5
Pipeline Directory of Glaucoma Pharmaceuticals in the US (As of March 2009).....III-5
Select Glaucoma Pharmaceuticals in Phase III Clinical Studies.....III-5
1$100
   Select Glaucoma Pharmaceuticals in Phase II Clinical Studies.....III-6
Select Glaucoma Pharmaceuticals in Phase I Clinical Studies.....III-6
Select New Drug Approvals.....III-6
1$100
   Strategic Corporate Developments.....III-74$375
   Select Players in the Region.....III-114$375
   B. Market Analytics.....III-15
Table 7: US Recent Past, Current & Future Analysis for Glaucoma Pharmaceuticals Market by Drug Class – Alpha Adrenergic Agonists, Beta-Blockers, Carbonic Anhydrase Inhibitors, Combination Therapies, Prostaglandin Analogues and Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-15
1$200
   Table 8: US 10-Year Perspective for Glaucoma Pharmaceuticals by Drug Class – Percentage Breakdown of Dollar Sales for Alpha Adrenergic Agonists, Beta-Blockers, Carbonic Anhydrase Inhibitors, Combination Therapies, Prostaglandin Analogues and Other Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....III-161$200
   A. Market Analysis.....III-17
Combination Drugs and Generics to Gain Traction.....III-17
1$100
   Table 9: Leading Glaucoma Pharmaceutical Products in Rest of World Market (2008, 2010 & 2012): Percentage Breakdown of Value Sales for Xalatan/Xalcom, Cosopt/Trusopt, Travatan/ Extravan, Lumigan/ Ganfort, Alphagan/Combigan, Timoptic/ XE, Generic Timolol and Others (includes corresponding Graph/Chart).....III-18
Focus on Glaucoma Market in Select Countries.....III-18
Canada.....III-18
Lack of Awareness: A Key Issue.....III-18
1$200
   Europe.....III-19
Glaucoma Pharmaceuticals Reimbursement in Europe.....III-19
1$100
   China.....III-20
Select Drug Approvals.....III-20
1$100
   Strategic Corporate Developments.....III-212$175
   Select Players.....III-232$175
   B. Market Analytics.....III-25
Table 10: Rest of World Recent Past, Current & Future Analysis for Glaucoma Pharmaceuticals – Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-25
1$200
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com